MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Humanized antibodies to treat diabetes, range of tissue injuries

University of Minnesota

SerpinB13 is a protease inhibitor linked to autoimmune inflammation and Type 1 diabetes (T1D).

Studies in mice treated with anti-serpinB13 antibody revealed increase in the number of pancreatic progenitor cells, expansion of islet mass and improved resistance to severe diabetes.

In humans, native anti-serpinB13 activity is associated with a slower progression to onset of T1D and a slower decline in the residual beta cell function in the first year after diabetes onset. Additionally, the serpinB13 antibody has regenerative properties.

The regenerative potential of serpinB13 antibody was underscored in studies on bone fracture and skin ulcers. In both instances, antibody treatment markedly accelerated bone and skin healing. Taken together, the serpinB13 antibody has potential therapeutic applications ranging from diabetes to acute forms of tissue injury.

Features/Benefits

  • Treats Type 1 Diabetes:> Administration of antibodies results in reduced inflammation and increased beta-cell proliferation.
  • Based on identified human biomarkers: Therapy complements natural autoantibodies associated with positive disease outcomes.
  • Reduced host immune reactivity: The humanized serpinB13 antibody mitigates immunogenic effects in humans.

Applications 

  • Diabetes
  • Inflammatory bowel disease
  • Psoriasis
  • Skin burn injury
  • Bone fractures
  • Hereditary hair loss

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    503 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw